BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sunshine Guojian Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sunshine Guojian Pharmaceutical's
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07261644-1795@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:Amdokitug (Yisaituo): Phase 3 readout est. (NCT07261644)
DESCRIPTION:Amdokitug (Yisaituo)\, phase 3.\nStudy: A Study to Evaluate the
  Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spond
 ylitis(AS)\nEstimated primary completion: 14 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/amdokitug-yisaituo#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07261644
URL:https://assetmemo.bio/drug/amdokitug-yisaituo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767253-1275@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SSGJ-611: Phase 3 readout est. (NCT07767253)
DESCRIPTION:SSGJ-611\, phase 3\, Atopic Dermatitis.\nStudy: Evaluation of 6
 11 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)\nEsti
 mated primary completion: September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ssgj-611#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07767253
URL:https://assetmemo.bio/drug/ssgj-611#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349329-1795@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20280419
DTEND;VALUE=DATE:20280420
SUMMARY:Amdokitug (Yisaituo): Phase 3 readout est. (NCT07349329)
DESCRIPTION:Amdokitug (Yisaituo)\, phase 3.\nStudy: A Study to Evaluate the
  Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondy
 loarthritis (Nr-axSpA)\nEstimated primary completion: 19 April 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/amdokitug-yisaituo#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07349329
URL:https://assetmemo.bio/drug/amdokitug-yisaituo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039669-1275@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SSGJ-611: Phase 3 readout est. (NCT07039669)
DESCRIPTION:SSGJ-611\, phase 3.\nStudy: Evaluation of 611 in Chinese Adults
  Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ssgj-611#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07039669
URL:https://assetmemo.bio/drug/ssgj-611#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507513-53@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SSGJ-627: Phase 2 readout est. (NCT07507513)
DESCRIPTION:SSGJ-627\, phase 2\, Ulcerative Colitis.\nStudy: The Purpose of
  This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment
  of UC\nEstimated primary completion: 28 February 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ssgj-627#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07507513
URL:https://assetmemo.bio/drug/ssgj-627#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
